ProQR Therapeutics N.V. announced that Noreen R. Henig, M.D., Chief Medical Officer, will leave ProQR effective November 4, 2017 to pursue a new opportunity, and will serve as a special advisor to the Company going forward. Chief Development Strategy Officer, David M. Rodman M.D, will assume leadership over clinical development. Additionally, the Company announced the promotion of Peter Adamson to Senior Vice President Ophthalmology Franchise and the promotion of Robert Friesen to Senior Vice President Science and Early Development. David M. Rodman, M.D., Chief Development Strategy Officer at ProQR, will lead clinical development at the Company. Dr. Rodman joined ProQR in March 2017 with extensive experience in rare disease drug development, translational medicine and RNA therapeutics, having previously served in leadership roles with Novartis Institute for Biomedical Research (NIBR), Vertex Pharmaceuticals, miRagen Therapeutics and Nivalis Therapeutics. In his promotion to SVP Ophthalmology Franchise, Peter Adamson, Ph.D., will be responsible for development of drugs to treat severe inherited ophthalmic diseases. Dr. Adamson joined ProQR in April 2015 as the Head of Ophthalmology Research. Formerly, Dr. Adamson was Vice President and Head of Ophthalmology Research at GlaxoSmithKline. He obtained his Ph.D. in Biochemistry from the University of London (Institute of Psychiatry) and subsequently worked as a postdoctoral researcher at the Institute of Cancer Research and Vascular Biology Research Centre before taking up an academic position at the UCL Institute of Ophthalmology from 1994-2004 where he was a group leader and Reader in Molecular Pathology. Dr. Adamson has authored over 100 peer-reviewed scientific publications in the domains of inflammation, ophthalmology and neurology and retains an honorary appointment at UCL, Institute of Ophthalmology where he is Professor of Molecular Pathology (Ophthalmology). In Robert Friesen, Ph.D.’s new role as SVP Science and Early Development, he will be overseeing the scientific advancement of the Company and will be responsible for non-clinical development. Dr. Friesen has served as Head of Innovation at the Company since June 2016. He obtained a M.S. in Biology from the University of Utrecht, and a Ph.D. in Biochemistry, at the University of Texas Medical Branch. Previously, Dr. Friesen was Vice President and Head of Biologics Research within Janssen R&D, a Johnson & Johnson company, where he led a global team of over 200 scientists responsible for the discovery and early development of biotherapeutics for all therapeutic areas. Before joining Janssen R&D, he held senior R&D positions at AM-Pharma, MorphoSys and Crucell. Dr. Friesen has authored a number of publications in high impact scientific journals, and participated in numerous invited lectures. He has also been awarded multiple patents in the field of biotechnology.